A total of 33 449 individuals (70.4%) with cooccurring SUD during baseline received treatment without MOUD during first treatment episode, compared with 69 481 individuals (52.7%) without cooccurring SUD (Table 1). Whereas 9651 individuals (20.3%) with cooccurring SUD received buprenorphine, 57 641 individuals (43.7%) without cooccurring SUD received buprenorphine. Conversely, whereas among those with cooccurring SUD, 1156 individuals (2.4%) received ER naltrexone and 3232 individuals (6.8%) received oral naltrexone, among those without cooccurring SUD, only 1935 individuals (1.5%) received ER naltrexone and 2735 individuals (2.1%) received oral naltrexone.
